---
document_datetime: 2025-12-13 23:33:55
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/denosumab-intas.html
document_name: denosumab-intas.html
version: success
processing_time: 0.0970294
conversion_datetime: 2025-12-27 20:12:11.533197
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Denosumab Intas

[RSS](/en/individual-human-medicine.xml/266955)

##### Authorised

This medicine is authorised for use in the European Union

denosumab Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Denosumab Intas](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Denosumab Intas is a medicine that contains the active substance denosumab and is used to treat the following conditions:

- osteoporosis (a disease that makes bones fragile) in women who have been through the menopause and in men who have an increased risk of fracture (broken bones). In women who have been through the menopause denosumab reduces the risk of fractures in the spine and elsewhere in the body, including in the hip;
- bone loss in men receiving treatment for prostate cancer that increases their risk of fractures; denosumab reduces the risk of fractures in the spine;
- bone loss in adults at increased risk of fractures who are treated long term with corticosteroid medicines given by mouth or injection.

Denosumab Intas is a biological medicine. It is a 'biosimilar medicine'; this means that Denosumab Intas is highly similar to another biological medicine (the 'reference medicine') that is already authorised in the EU. The reference medicine for Denosumab Intas is Prolia. For more information on biosimilar medicines, see [here](https://www.ema.europa.eu/en/human-regulatory/overview/biosimilar-medicines) .

Expand section

Collapse section

## How is Denosumab Intas used?

Denosumab Intas is available as a solution for injection in prefilled syringes.

Denosumab Intas is given once every 6 months as an injection under the skin in the thigh, abdomen (belly) or back of the arm. During treatment with Denosumab Intas, the doctor should ensure that the patient is receiving calcium and vitamin D supplements. Denosumab Intas can be given by someone who has been trained in how to give injections appropriately.

The medicine can only be obtained with a prescription.

For more information about using Denosumab Intas, see the package leaflet or contact your doctor or pharmacist.

## How does Denosumab Intas work?

The active substance in Denosumab Intas, denosumab, is a monoclonal antibody (a type of protein) that has been designed to recognise and attach to a specific structure in the body called RANKL. RANKL is involved in activating osteoclasts, the cells in the body that are involved in breaking down bone tissue. By attaching to and blocking RANKL, denosumab reduces the formation and activity of the osteoclasts.

This reduces the loss of bone and maintains bone strength, making fractures less likely to happen.

## What benefits of Denosumab Intas have been shown in studies?

Laboratory studies comparing Denosumab Intas with Prolia have shown that the active substance in Denosumab Intas is highly similar to that in Prolia in terms of structure, purity and biological activity. Studies have also shown that giving Denosumab Intas produces similar levels of the active substance in the body to those seen with Prolia.

In addition, a study in 522 women with osteoporosis who have been through the menopause compared the effectiveness of Denosumab Intas with that of Prolia. After a year of treatment, bone mineral density (a measure of how strong the bones are) in the spine increased by around 6% in both women who received Denosumab Intas and those who received Prolia.

Because Denosumab Intas is a biosimilar medicine, the studies on the effectiveness of denosumab carried out with Prolia do not all need to be repeated for Denosumab Intas.

## What are the risks associated with Denosumab Intas?

The safety of Denosumab Intas has been evaluated and, on the basis of all the studies carried out, the side effects of the medicine are considered to be comparable to those of the reference medicine Prolia.

For the complete list of side effects and restrictions of Denosumab Intas, see the package leaflet.

The most common side effects with Denosumab Intas (which may affect more than 1 in 10 people) include pain in the arms or legs, and bone, joint and muscle pain. Uncommon side effects (which may affect up to 1 in 100 people) include cellulitis (inflammation of deep skin tissue). Rare side effects (which may affect up to 1 in 1,000 people) include hypocalcaemia (low blood calcium), hypersensitivity (allergy), osteonecrosis of the jaw (damage to the bones of the jaw, which could lead to pain, sores in the mouth or loosening of teeth) and unusual fractures of the thigh bone.

Denosumab Intas must not be used in people with hypocalcaemia (low blood calcium levels).

## Why is Denosumab Intas authorised in the EU?

The European Medicines Agency decided that, in accordance with EU requirements for biosimilar medicines, Denosumab Intas has a highly similar structure, purity and biological activity to Prolia and is distributed in the body in the same way. In addition, a study has shown that Denosumab Intas and Prolia are equivalent in terms of safety and benefits in women with osteoporosis who have been through the menopause.

All these data were considered sufficient to conclude that Denosumab Intas will have the same effects as Prolia in its authorised uses. Therefore, the Agency's view was that, as for Prolia, the benefits of Denosumab Intas outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Denosumab Intas?

The company that markets Denosumab Intas will provide a card to inform patients about the risk of osteonecrosis of the jaw and to instruct them to contact their doctor if they experience symptoms.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Denosumab Intas have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Denosumab Intas are continuously monitored. Suspected side effects reported with Denosumab Intas are carefully evaluated and any necessary action taken to protect patients.

## Other information about Denosumab Intas

Denosumab Intas received a marketing authorisation valid throughout the EU on 17 November 2025.

Denosumab Intas : EPAR - Medicine overview

Reference Number: EMA/329167/2025

English (EN) (135.56 KB - PDF)

**First published:** 04/12/2025

[View](/en/documents/overview/denosumab-intas-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-924)

български (BG) (161.49 KB - PDF)

**First published:**

04/12/2025

[View](/bg/documents/overview/denosumab-intas-epar-medicine-overview_bg.pdf)

español (ES) (134.87 KB - PDF)

**First published:**

04/12/2025

[View](/es/documents/overview/denosumab-intas-epar-medicine-overview_es.pdf)

čeština (CS) (158.62 KB - PDF)

**First published:**

04/12/2025

[View](/cs/documents/overview/denosumab-intas-epar-medicine-overview_cs.pdf)

dansk (DA) (134.94 KB - PDF)

**First published:**

04/12/2025

[View](/da/documents/overview/denosumab-intas-epar-medicine-overview_da.pdf)

Deutsch (DE) (138.32 KB - PDF)

**First published:**

04/12/2025

[View](/de/documents/overview/denosumab-intas-epar-medicine-overview_de.pdf)

eesti keel (ET) (132.62 KB - PDF)

**First published:**

04/12/2025

[View](/et/documents/overview/denosumab-intas-epar-medicine-overview_et.pdf)

ελληνικά (EL) (161.01 KB - PDF)

**First published:**

04/12/2025

[View](/el/documents/overview/denosumab-intas-epar-medicine-overview_el.pdf)

français (FR) (136.79 KB - PDF)

**First published:**

04/12/2025

[View](/fr/documents/overview/denosumab-intas-epar-medicine-overview_fr.pdf)

hrvatski (HR) (155.76 KB - PDF)

**First published:**

04/12/2025

[View](/hr/documents/overview/denosumab-intas-epar-medicine-overview_hr.pdf)

italiano (IT) (134.25 KB - PDF)

**First published:**

04/12/2025

[View](/it/documents/overview/denosumab-intas-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (165.33 KB - PDF)

**First published:**

04/12/2025

[View](/lv/documents/overview/denosumab-intas-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (155.62 KB - PDF)

**First published:**

04/12/2025

[View](/lt/documents/overview/denosumab-intas-epar-medicine-overview_lt.pdf)

magyar (HU) (157.49 KB - PDF)

**First published:**

04/12/2025

[View](/hu/documents/overview/denosumab-intas-epar-medicine-overview_hu.pdf)

Malti (MT) (159.25 KB - PDF)

**First published:**

04/12/2025

[View](/mt/documents/overview/denosumab-intas-epar-medicine-overview_mt.pdf)

Nederlands (NL) (135.92 KB - PDF)

**First published:**

04/12/2025

[View](/nl/documents/overview/denosumab-intas-epar-medicine-overview_nl.pdf)

polski (PL) (160.81 KB - PDF)

**First published:**

04/12/2025

[View](/pl/documents/overview/denosumab-intas-epar-medicine-overview_pl.pdf)

português (PT) (135.82 KB - PDF)

**First published:**

04/12/2025

[View](/pt/documents/overview/denosumab-intas-epar-medicine-overview_pt.pdf)

română (RO) (153.83 KB - PDF)

**First published:**

04/12/2025

[View](/ro/documents/overview/denosumab-intas-epar-medicine-overview_ro.pdf)

slovenčina (SK) (158.99 KB - PDF)

**First published:**

04/12/2025

[View](/sk/documents/overview/denosumab-intas-epar-medicine-overview_sk.pdf)

slovenščina (SL) (156.07 KB - PDF)

**First published:**

04/12/2025

[View](/sl/documents/overview/denosumab-intas-epar-medicine-overview_sl.pdf)

Suomi (FI) (132.35 KB - PDF)

**First published:**

04/12/2025

[View](/fi/documents/overview/denosumab-intas-epar-medicine-overview_fi.pdf)

svenska (SV) (133.45 KB - PDF)

**First published:**

04/12/2025

[View](/sv/documents/overview/denosumab-intas-epar-medicine-overview_sv.pdf)

Denosumab Intas : EPAR - Risk management plan

English (EN) (648.78 KB - PDF)

**First published:** 04/12/2025

[View](/en/documents/rmp/denosumab-intas-epar-risk-management-plan_en.pdf)

## Product information

Denosumab Intas : EPAR - Product information

English (EN) (702.76 KB - PDF)

**First published:** 04/12/2025

[View](/en/documents/product-information/denosumab-intas-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-90)

български (BG) (803.04 KB - PDF)

**First published:**

04/12/2025

[View](/bg/documents/product-information/denosumab-intas-epar-product-information_bg.pdf)

español (ES) (777.7 KB - PDF)

**First published:**

04/12/2025

[View](/es/documents/product-information/denosumab-intas-epar-product-information_es.pdf)

čeština (CS) (779.71 KB - PDF)

**First published:**

04/12/2025

[View](/cs/documents/product-information/denosumab-intas-epar-product-information_cs.pdf)

dansk (DA) (716.04 KB - PDF)

**First published:**

04/12/2025

[View](/da/documents/product-information/denosumab-intas-epar-product-information_da.pdf)

Deutsch (DE) (698.72 KB - PDF)

**First published:**

04/12/2025

[View](/de/documents/product-information/denosumab-intas-epar-product-information_de.pdf)

eesti keel (ET) (743.69 KB - PDF)

**First published:**

04/12/2025

[View](/et/documents/product-information/denosumab-intas-epar-product-information_et.pdf)

ελληνικά (EL) (699.08 KB - PDF)

**First published:**

04/12/2025

[View](/el/documents/product-information/denosumab-intas-epar-product-information_el.pdf)

français (FR) (795.25 KB - PDF)

**First published:**

04/12/2025

[View](/fr/documents/product-information/denosumab-intas-epar-product-information_fr.pdf)

hrvatski (HR) (911.69 KB - PDF)

**First published:**

04/12/2025

[View](/hr/documents/product-information/denosumab-intas-epar-product-information_hr.pdf)

íslenska (IS) (739.38 KB - PDF)

**First published:**

04/12/2025

[View](/is/documents/product-information/denosumab-intas-epar-product-information_is.pdf)

italiano (IT) (727.85 KB - PDF)

**First published:**

04/12/2025

[View](/it/documents/product-information/denosumab-intas-epar-product-information_it.pdf)

latviešu valoda (LV) (766.51 KB - PDF)

**First published:**

04/12/2025

[View](/lv/documents/product-information/denosumab-intas-epar-product-information_lv.pdf)

lietuvių kalba (LT) (776.93 KB - PDF)

**First published:**

04/12/2025

[View](/lt/documents/product-information/denosumab-intas-epar-product-information_lt.pdf)

magyar (HU) (843.83 KB - PDF)

**First published:**

04/12/2025

[View](/hu/documents/product-information/denosumab-intas-epar-product-information_hu.pdf)

Malti (MT) (807.34 KB - PDF)

**First published:**

04/12/2025

[View](/mt/documents/product-information/denosumab-intas-epar-product-information_mt.pdf)

Nederlands (NL) (678.7 KB - PDF)

**First published:**

04/12/2025

[View](/nl/documents/product-information/denosumab-intas-epar-product-information_nl.pdf)

norsk (NO) (744.56 KB - PDF)

**First published:**

04/12/2025

[View](/no/documents/product-information/denosumab-intas-epar-product-information_no.pdf)

polski (PL) (863.4 KB - PDF)

**First published:**

04/12/2025

[View](/pl/documents/product-information/denosumab-intas-epar-product-information_pl.pdf)

português (PT) (771.22 KB - PDF)

**First published:**

04/12/2025

[View](/pt/documents/product-information/denosumab-intas-epar-product-information_pt.pdf)

română (RO) (783.59 KB - PDF)

**First published:**

04/12/2025

[View](/ro/documents/product-information/denosumab-intas-epar-product-information_ro.pdf)

slovenčina (SK) (789.45 KB - PDF)

**First published:**

04/12/2025

[View](/sk/documents/product-information/denosumab-intas-epar-product-information_sk.pdf)

slovenščina (SL) (775.5 KB - PDF)

**First published:**

04/12/2025

[View](/sl/documents/product-information/denosumab-intas-epar-product-information_sl.pdf)

Suomi (FI) (708.17 KB - PDF)

**First published:**

04/12/2025

[View](/fi/documents/product-information/denosumab-intas-epar-product-information_fi.pdf)

svenska (SV) (747.3 KB - PDF)

**First published:**

04/12/2025

[View](/sv/documents/product-information/denosumab-intas-epar-product-information_sv.pdf)

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Denosumab Intas : EPAR - All authorised presentations

English (EN) (203.93 KB - PDF)

**First published:** 04/12/2025

[View](/en/documents/all-authorised-presentations/denosumab-intas-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-672)

български (BG) (192 KB - PDF)

**First published:**

04/12/2025

[View](/bg/documents/all-authorised-presentations/denosumab-intas-epar-all-authorised-presentations_bg.pdf)

español (ES) (206.58 KB - PDF)

**First published:**

04/12/2025

[View](/es/documents/all-authorised-presentations/denosumab-intas-epar-all-authorised-presentations_es.pdf)

čeština (CS) (166.67 KB - PDF)

**First published:**

04/12/2025

[View](/cs/documents/all-authorised-presentations/denosumab-intas-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (185.65 KB - PDF)

**First published:**

04/12/2025

[View](/da/documents/all-authorised-presentations/denosumab-intas-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (207.39 KB - PDF)

**First published:**

04/12/2025

[View](/de/documents/all-authorised-presentations/denosumab-intas-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (182.48 KB - PDF)

**First published:**

04/12/2025

[View](/et/documents/all-authorised-presentations/denosumab-intas-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (161.95 KB - PDF)

**First published:**

04/12/2025

[View](/el/documents/all-authorised-presentations/denosumab-intas-epar-all-authorised-presentations_el.pdf)

français (FR) (185.05 KB - PDF)

**First published:**

04/12/2025

[View](/fr/documents/all-authorised-presentations/denosumab-intas-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (182.33 KB - PDF)

**First published:**

04/12/2025

[View](/hr/documents/all-authorised-presentations/denosumab-intas-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (111.62 KB - PDF)

**First published:**

04/12/2025

[View](/is/documents/all-authorised-presentations/denosumab-intas-epar-all-authorised-presentations_is.pdf)

italiano (IT) (214.79 KB - PDF)

**First published:**

04/12/2025

[View](/it/documents/all-authorised-presentations/denosumab-intas-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (222.29 KB - PDF)

**First published:**

04/12/2025

[View](/lv/documents/all-authorised-presentations/denosumab-intas-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (184.51 KB - PDF)

**First published:**

04/12/2025

[View](/lt/documents/all-authorised-presentations/denosumab-intas-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (117.87 KB - PDF)

**First published:**

04/12/2025

[View](/hu/documents/all-authorised-presentations/denosumab-intas-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (114.15 KB - PDF)

**First published:**

04/12/2025

[View](/mt/documents/all-authorised-presentations/denosumab-intas-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (181.75 KB - PDF)

**First published:**

04/12/2025

[View](/nl/documents/all-authorised-presentations/denosumab-intas-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (186.79 KB - PDF)

**First published:**

04/12/2025

[View](/no/documents/all-authorised-presentations/denosumab-intas-epar-all-authorised-presentations_no.pdf)

polski (PL) (186.63 KB - PDF)

**First published:**

04/12/2025

[View](/pl/documents/all-authorised-presentations/denosumab-intas-epar-all-authorised-presentations_pl.pdf)

português (PT) (185.37 KB - PDF)

**First published:**

04/12/2025

[View](/pt/documents/all-authorised-presentations/denosumab-intas-epar-all-authorised-presentations_pt.pdf)

română (RO) (184.24 KB - PDF)

**First published:**

04/12/2025

[View](/ro/documents/all-authorised-presentations/denosumab-intas-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (186.71 KB - PDF)

**First published:**

04/12/2025

[View](/sk/documents/all-authorised-presentations/denosumab-intas-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (109.57 KB - PDF)

**First published:**

04/12/2025

[View](/sl/documents/all-authorised-presentations/denosumab-intas-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (181.05 KB - PDF)

**First published:**

04/12/2025

[View](/fi/documents/all-authorised-presentations/denosumab-intas-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (184.08 KB - PDF)

**First published:**

04/12/2025

[View](/sv/documents/all-authorised-presentations/denosumab-intas-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Denosumab Intas Active substance denosumab International non-proprietary name (INN) or common name denosumab Therapeutic area (MeSH)

- Bone Resorption
- Osteoporosis
- Osteoporosis, Postmenopausal

Anatomical therapeutic chemical (ATC) code M05BX04

### Pharmacotherapeutic group

Drugs for treatment of bone diseases

### Therapeutic indication

Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal women denosumab significantly reduces the risk of vertebral, non-vertebral and hip fractures.

Treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures (see section 5.1). In men with prostate cancer receiving hormone ablation, denosumab significantly reduces the risk of vertebral fractures.

Treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture (see section 5.1).

## Authorisation details

EMA product number EMEA/H/C/006797

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Biosimilar

This is a biosimilar medicine, which is a biological medicine highly similar to another already approved biological medicine called the 'reference medicine'. For more information, see [Biosimilar medicines](/node/68323) .

Marketing authorisation holder

Intas Third Party Sales 2005 S.L.

Moll De Barcelona S/n Edificio Este World Trade Center 6 Planta 08039 Barcelona Spain

Opinion adopted 18/09/2025 Marketing authorisation issued 17/11/2025

## Assessment history

## Initial marketing authorisation documents

Denosumab Intas : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/311939/2025

English (EN) (2.29 MB - PDF)

**First published:** 04/12/2025

[View](/en/documents/assessment-report/denosumab-intas-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Denosumab Intas

Adopted

Reference Number: EMA/CHMP/297735/2025

English (EN) (140.35 KB - PDF)

**First published:** 19/09/2025

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-denosumab-intas_en.pdf)

#### News on Denosumab Intas

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 15-18 September 2025](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-15-18-september-2025) 19/09/2025

**This page was last updated on** 04/12/2025

## Share this page

[Back to top](#main-content)